Katie Anderson
Katie brings nearly two decades of editorial experience in business-to-business media. After earning her master’s degree in journalism, she began her career at the personal care R&D trade journal Cosmetics & Toiletries. There, she thrived on the constant flow of knowledge gained from interviewing chemists, regulatory experts, formulators and testing professionals in the field.
After nearly eight years with Cosmetics & Toiletries, Katie pursued her passion for skin physiology and ingredient science as Managing Editor of the professional esthetics brand Skin Inc. That same year, she also took on the role of Conference Director for Face and Body, where she developed and managed the event’s educational programming.
Following an acquisition, Katie was promoted to Editor-in-Chief of five professional media brands: Nailpro, Skin Inc., Beauty Launchpad, Medical Esthetics, and WellSpa 360.
Throughout her 19-year editorial career, Katie has held a variety of roles, but her passion has always been scientific editorial. She is the recipient of a bronze Folio Eddie Award for a single science article. She has frequently contributed her expertise as a guest speaker on industry podcasts, webcasts, conferences and video interviews. A lifelong learner, she enjoys the challenge of translating complex technical content into material that is both accurate and accessible.
Connect with Katie on LinkedIn: https://www.linkedin.com/in/katieanderson121/
ARTICLES BY KATIE ANDERSON
-
![Speed, performance-GettyImages-2236843403]( "AI Governance Is Just Like Driving A Race Car")
AI Governance Is Just Like Driving A Race Car9/1/2026Though some skeptics remain, nearly every business is at some stage of AI adoption. The technology has proven applications in pharmaceutical manufacturing, but effective governance must keep pace with its rapid development. That challenge is familiar to Bill Reid, healthcare and life sciences lead in Google’s Chief Information Security Office (CISO).
-
![Medicine, pills-GettyImages-186846700]( "Can U.S. Policy Bring Generic Drug Manufacturing Back Home?")
Can U.S. Policy Bring Generic Drug Manufacturing Back Home?8/25/2026Generic medicines imported into the U.S. were not subject to the recently imposed tariffs on imported pharmaceuticals, but President Trump posted in July that this could change within two years.
-
![AI, Medical innovation, digital healthcare diagnostics-GettyImages-2280077012]( "AI Needs Human Oversight To Better GMP Documentation")
AI Needs Human Oversight To Better GMP Documentation8/12/2026In a Pharmaceutical Online Live discussion on building inspection-ready systems with digital documentation, panelists emphasized that AI can accelerate review, trend analysis, and inspection response, but only when governed, validated, and kept firmly under human quality oversight.
-
![capsules, pills with puerto rico flag-GettyImages-481936824]( "6 Reasons Pharma Manufacturing Has Eyes On Puerto Rico")
6 Reasons Pharma Manufacturing Has Eyes On Puerto Rico8/1/2026Several advantages explain why Puerto Rico continues to attract pharma investment, especially as manufacturers reassess supply chain risk and look for options closer to the U.S. mainland.
-
![Technology, Communication, and Innovation-GettyImages-2284811011]( "Building AI Readiness Through Cross Collaboration")
Building AI Readiness Through Cross Collaboration7/22/2026AbbVie’s Operations Quality Assurance Innovation Accelerator offers a practical model for moving from AI enthusiasm to governed, people-centered execution.
-
![Solida-1 central spine connecting production and logistics module]( "Bayer Adds A Spine To Modularity For Scale Without Disruption")
Bayer Adds A Spine To Modularity For Scale Without Disruption7/16/2026Modular facility concepts offer a different path, giving manufacturers the ability to expand capacity stepwise, standardize core infrastructure, and adapt production environments as product portfolios evolve
-
![Pharmaceutical production-GettyImages-1417392227]( "7 Facilities Pilot PreCheck for Faster Approval")
7 Facilities Pilot PreCheck for Faster Approval7/13/2026A more streamlined path to operational new pharmaceutical facilities in the U.S. may be on the horizon. Nearly a year after the PreCheck Pilot Program was introduced by the U.S. Food and Drug Administration (FDA) in August 2025, the first seven participating facilities have been announced.
-
![02_Left-side building FJ3_Right-side building FJ2]( "Inside Chugai's Digital Infrastructure Strategy")
Inside Chugai's Digital Infrastructure Strategy6/29/2026When a facility is fully automated and designed for manufacturing flexibility, it needs a digital infrastructure that pulls the systems together, reports data accurately and efficiently, and recognizes areas for continuous improvement.
-
![process control for monoclonal antibodies, recombinant proteins, probiotics, GLP-1 production-GettyImages-2281853896]( "[VIDEO] GLP-1 Manufacturing's New Bottlenecks At Multi-Ton Scale")
[VIDEO] GLP-1 Manufacturing's New Bottlenecks At Multi-Ton Scale6/24/2026“At multi-ton scale, the challenge becomes less about making the molecule and more about controlling the variability of the process in this interconnected system,” explained Villain.
-
![white coupon banner, great topic-GettyImages-2271702407]( "Let Your Voice Help Shape Pharma Manufacturing")
Let Your Voice Help Shape Pharma Manufacturing6/17/2026Pharmaceutical Online hosts live virtual panels with industry experts on important topics and challenges, and we want to know what topics are important to you. Please consider taking a few minutes of your time to tell us what they are.
